Faculty of Medicine, Department for Internal Medicine, University of Belgrade, Belgrade, Serbia.
Clinic for Pulmonology, University Clinical Center of Serbia, Belgrade, Serbia.
BMC Pulm Med. 2024 Aug 9;24(1):385. doi: 10.1186/s12890-024-03196-2.
The aim of our study was to investigate serum chitotriosidase level in tuberculosis patients, its relationship with microbiological and clinical parameters, and response to treatment.
This longitudinal panel study included 149 patients with confirmed TB disease. Serum chitotriosidase activity was measured at the beginning and the end of treatment. Factors associated with chitotriosidase activity were explored using univariate and multivariable logistic regression analysis.
Out of 149 study participants, 71(47.7%) were female. The mean age was 53.0 (SD = 18.2). Majority of cases were new 118(79.2), predominantly 145 (97.3%) having pulmonary tuberculosis. More than half of the patients were sputum smear positive 91 (61.1%) while culture positive in 146 (98%) of them. According to radiological findings, cavitary lesions were found in 92 (63.4%) patients. Anti TB treatment was associated with significant decrease in serum chitotriosidase level (< 0.001). New TB treatment (OR = 4.41%;95% CI = 1.20-9.89), and cavitary lesions (OR = 3.86;95%CI = 0,59-26.57) were found to be significantly associated with decrease of chitotriosidase activity.
The results of our study showed that serum chitotriosidase values are strong biomarkers for starting anti TB treatment and for treatment monitoring, since decrease in serum chitotriosidase level can predict favorable treatment response in patients with tuberculosis. Further studies are needed to explore these, and other factors associated with chitotriosidase activity among tuberculosis patients.
本研究旨在探讨结核患者血清壳三糖苷酶水平及其与微生物学和临床参数的关系，以及对治疗的反应。
这是一项纵向病例研究，纳入了 149 例确诊结核病患者。在治疗开始和结束时测量血清壳三糖苷酶活性。使用单变量和多变量逻辑回归分析探讨与壳三糖苷酶活性相关的因素。
在 149 名研究参与者中，71 名（47.7%）为女性。平均年龄为 53.0（SD=18.2）。大多数为新发 118 例（79.2%），主要为 145 例（97.3%）肺结核。超过一半的患者痰涂片阳性 91 例（61.1%），培养阳性 146 例（98%）。根据影像学发现，92 例（63.4%）患者有空洞病变。抗结核治疗与血清壳三糖苷酶水平显著下降相关（<0.001）。新发结核病治疗（OR=4.41%；95%CI=1.20-9.89）和空洞病变（OR=3.86；95%CI=0.59-26.57）与壳三糖苷酶活性下降显著相关。
本研究结果表明，血清壳三糖苷酶值是启动抗结核治疗和监测治疗的有力生物标志物，因为血清壳三糖苷酶水平的降低可以预测结核病患者的治疗反应良好。需要进一步研究来探讨这些因素以及与结核病患者壳三糖苷酶活性相关的其他因素。
